Lisa den Hollander
PhD candidate / internal
- Name
- L.S. den Hollander MSc
- Telephone
- +31 71 527 2727
- l.s.den.hollander@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0002-8954-3460
In 2013, I started my bachelor Pharmaceutical Sciences at Leiden University with a minor in pharmacy. During my internship at the Department of Medicinal Chemistry in 2015, I worked on finding new intracellular allosteric antagonists for CC chemokine receptor 5. I expanded on my bachelor project during my 9 months internship for my Master’s in Biopharmaceutical Sciences. In addition, I explored the possibilities of the compound’s probe dependent characteristics. My second internship I performed at the Department of Clinical Chemistry and Hematology, where I was involved in the development of an experimental model for extracellular vesicle transfer in cancer cells. After obtaining my Master’s degree, I decided to further explore my interests in chemical pharmacology and joined the lab of Prof. Dr. Ad IJzerman in the Dr. Laura Heitman group. During my PhD, I will again focus on CC chemokine receptors and explore concepts in drug discovery such as allosteric modulation, precision medicine and functional selectivity in combination with drug binding kinetics.
PhD candidate / internal
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Medicinal Chemistry
- Hollander L.S. den, IJzerman A.P. & Heitman L.H. (2024), Pharmacological characterization of allosteric modulators: a case for chemokine receptors, Medicinal Research Reviews : 1-16.
- Hollander L.S. den (25 September 2024), From every angle: novel insights into CC chemokine receptor 2 pharmacology (Dissertatie. Leiden Academic Centre for Drug Research (LACDR), Faculty of Science, Leiden University). Supervisor(s): Heitman A.P. & Heitman L.H.
- den Hollander Lisa S. Zweemer Annelien J.M. Béquignon Olivier J.M. Hammerl Dora M. Bleijs Bente T.M. Veenhuizen Margo Lantsheer Wernard J.F. Chau Bobby van Westen Gerard J.P. IJzerman Adriaan P. Heitman Laura H. (2024), CC chemokine receptor 2 is allosterically modulated by sodium ions and amiloride derivatives through a distinct sodium ion binding site, Biochemical Pharmacology 229: 116464.
- Hollander L.S. den, Béquignon O.J.M., Wang X., Wezel K. van, Broekhuis J., Gorostiola González M., Visser K.E. de, IJzerman A.P., Westen G.J.P. van & Heitman L.H. (2022), Impact of cancer-associated mutations in CC chemokine receptor 2 on receptor function and antagonism, Biochemical Pharmacology 208: 115399.
- Ortiz Zacarías N.V., Veldhoven J.P.D. van, Hollander L.S. den, Dogan B., Openy J., Hsiao Y.Y., Lenselink E.B., Heitman L.H. & IJzerman A.P. (2019), Synthesis and Pharmacological Evaluation of Triazolopyrimidinone Derivatives as Noncompetitive, Intracellular Antagonists for CC Chemokine Receptors 2 and 5, Journal of Medicinal Chemistry 62(24): 11035-11053.